Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway

The prognosis of gastric Cancer (GC) remains poor due to clinical drug resistance, and novel drugs are urgently needed. Apoptin-derived peptide (AdP) is an antitumor polypeptide constructed in our laboratory that has been used to combat cisplatin (CDDP) resistance in GC cells. MTT and colony-formation assays and Hoechst 33342 staining were used to measure the cytotoxicity of CDDP and AdP in GC cells. Cell Apoptosis was measured using an Annexin-V-FITC/PI dual staining assay. Western blot analysis was conducted to detect the expression of proteins in the PI3K/Akt signaling pathway and resistance-related markers. AdP exerted a specific cytotoxic effect on GC cells and CDDP-resistant GC cells in a concentration- and time-dependent manner. AdP also suppressed cell invasion and migration. Additionally, AdP inhibited the expression of p85, Akt, p-p85, p-AKT, multidrug resistance 1 (MDR1), and aryl hydrocarbon nuclear translocator (ARNT) in the PI3K/Akt/ARNT signaling pathway, which promoted Apoptosis and necrosis in GC cells. AdP promoted Apoptosis in CDDP-resistant GC cells by suppressing the PI3K/Akt/ARNT signaling pathway and might be considered a candidate agent for the clinical treatment of cisplatin-resistant GC.

Apoptin-derived peptide; PI3K/AKT/ARNT; cisplatin resistance; gastric cancer.